{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:56:55Z","timestamp":1790611015393,"version":"4.1.0"},"reference-count":67,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.beem.2026.102154","type":"journal-article","created":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T06:09:11Z","timestamp":1786774151000},"page":"102154","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Thyroid eye disease: Established and emerging therapies"],"prefix":"10.1016","volume":"40","author":[{"given":"Emma","family":"Samia-Aly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Penarrocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivaa","family":"Ramsewak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaveh","family":"Vahdani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Verity","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmy M.","family":"Uddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.beem.2026.102154_bib1","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMra0905750","article-title":"Graves\u2019 ophthalmopathy","volume":"362","author":"Bahn","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beem.2026.102154_bib2","series-title":"Thyroid Eye Disease: A Comprehensive Guide","author":"Ford","year":"2025"},{"issue":"3\u20134","key":"10.1016\/j.beem.2026.102154_bib3","first-page":"177","article-title":"Development and course of exophthalmos and ophthalmoplegia in Graves\u2019 disease with special reference to the effect of thyroidectomy","volume":"5","author":"Rundle","year":"1945","journal-title":"Clin Sci"},{"issue":"4S_1","key":"10.1016\/j.beem.2026.102154_bib4","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1097\/IOP.0000000000001147","article-title":"Phenotypes of thyroid eye disease","volume":"34","author":"Uddin","year":"2018","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"3","key":"10.1016\/j.beem.2026.102154_bib5","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1089\/thy.2010.1619","article-title":"improving outcomes for thyroid eye disease--the Amsterdam Declaration","volume":"20","author":"Graves\u2019","year":"2010","journal-title":"Thyroid"},{"issue":"4","key":"10.1016\/j.beem.2026.102154_bib6","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1365-2265.1993.tb00516.x","article-title":"Age and gender influence the severity of thyroid-associated ophthalmopathy: a study of 101 patients attending a combined thyroid-eye clinic","volume":"38","author":"Perros","year":"1993","journal-title":"Clin Endocrinol"},{"issue":"5","key":"10.1016\/j.beem.2026.102154_bib7","first-page":"632","article-title":"Clinical activity score as a guide in the management of patients with Graves\u2019 ophthalmopathy","volume":"47","author":"Mourits","year":"1997","journal-title":"Clin Endocrinol"},{"issue":"5","key":"10.1016\/j.beem.2026.102154_bib8","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/01.iop.0000235499.34867.85","article-title":"VISA Classification for Graves orbitopathy","volume":"22","author":"Dolman","year":"2006","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"6","key":"10.1016\/j.beem.2026.102154_bib9","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1530\/EJE-18-0039","article-title":"EUGOGO (European Group on Graves\u2019 Orbitopathy). Predictive score for the development or progression of Graves\u2019 orbitopathy in patients with newly diagnosed Graves\u2019 hyperthyroidism","volume":"178","author":"Wiersinga","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"10.1016\/j.beem.2026.102154_bib10","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/01676830802414566","article-title":"Development and validation of a patient symptom questionnaire to facilitate early diagnosis of thyroid-associated Orbitopathy in Graves' disease","volume":"27","author":"Mohaseb","year":"2008","journal-title":"Orbit"},{"issue":"3","key":"10.1016\/j.beem.2026.102154_bib11","doi-asserted-by":"crossref","first-page":"E458","DOI":"10.1210\/jc.2014-3146","article-title":"Diagnosis of Graves\u2019 orbitopathy (DiaGO): results of a pilot study to assess the utility of an office tool for practicing endocrinologists","volume":"100","author":"Mitchell","year":"2015","journal-title":"J Clin Endocrinol Metabol"},{"issue":"3","key":"10.1016\/j.beem.2026.102154_bib12","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/01676830.2017.1280057","article-title":"Thyroid Eye Disease Amsterdam Declaration Implementation Group (TEAMeD). Management of thyroid eye disease in the United Kingdom: a multi-centre thyroid eye disease audit","volume":"36","author":"Mellington","year":"2017","journal-title":"Orbit"},{"issue":"4","key":"10.1016\/j.beem.2026.102154_bib13","doi-asserted-by":"crossref","first-page":"G43","DOI":"10.1530\/EJE-21-0479","article-title":"The 2021 European Group on Graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy","volume":"185","author":"Bartalena","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"10.1016\/j.beem.2026.102154_bib14","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1007\/s002680010216","article-title":"Surgery for Graves' disease: total versus subtotal thyroidectomy-results of a prospective randomized trial","volume":"24","author":"Witte","year":"2000","journal-title":"World J Surg"},{"issue":"2","key":"10.1016\/j.beem.2026.102154_bib15","first-page":"147","article-title":"Graves\u2019 ophthalmopathy and tobacco smoking","volume":"129","author":"Tallstedt","year":"1993","journal-title":"Acta Endocrinol"},{"issue":"20","key":"10.1016\/j.beem.2026.102154_bib16","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa1012985","article-title":"European Group on Graves' Orbitopathy. Selenium and the course of mild Graves' orbitopathy","volume":"364","author":"Marcocci","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beem.2026.102154_bib17","doi-asserted-by":"crossref","DOI":"10.1530\/EC-24-0259","article-title":"Psychological aspects of Graves\u2019 ophthalmopathy","author":"Al-Badri","year":"2024","journal-title":"Endocr Connect"},{"issue":"9","key":"10.1016\/j.beem.2026.102154_bib18","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1038\/s41433-019-0664-z","article-title":"A survey of current practices by the British Oculoplastic Surgery Society (BOPSS) and recommendations for delivering a sustainable multidisciplinary approach to thyroid eye disease in the United Kingdom","volume":"34","author":"Lee","year":"2020","journal-title":"Eye"},{"issue":"1","key":"10.1016\/j.beem.2026.102154_bib19","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1210\/clinem\/dgad476","article-title":"A randomized clinical trial of intravenous methylprednisolone with 2 protocols in patients with Graves orbitopathy","volume":"109","author":"Li","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.beem.2026.102154_bib20","doi-asserted-by":"crossref","first-page":"5234","DOI":"10.1210\/jc.2005-0148","article-title":"single blind trial of intrave\u00acnous versus oral steroid monotherapy in Graves\u2019 orbitopathy","volume":"90","author":"Kahaly","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"7462","key":"10.1016\/j.beem.2026.102154_bib21","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1136\/bmj.329.7462.385","article-title":"Recent developments in thyroid eye disease","volume":"329","author":"Cawood","year":"2004","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.beem.2026.102154_bib22","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/IOP.0000000000000544","article-title":"Orbital radiation therapy in thyroid eye disease","volume":"32","author":"Chundury","year":"2016","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"5","key":"10.1016\/j.beem.2026.102154_bib23","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s00417-016-3280-7","article-title":"Efficacy of combined orbital radiation and systemic steroids in the management of Graves' orbitopathy","volume":"254","author":"Kim","year":"2016","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"10.1016\/j.beem.2026.102154_bib24","article-title":"Orbital radiotherapy plus concomitant steroids in moderate-to-severe Graves' ophthalmopathy: good results after long-term follow-up","volume":"17","author":"Nicosia","year":"2019","journal-title":"Int J Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.beem.2026.102154_bib25","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1089\/105072502753600223","article-title":"Orbital radiotherapy for Graves' ophthalmopathy","volume":"12","author":"Bartalena","year":"2002","journal-title":"Thyroid"},{"issue":"288","key":"10.1016\/j.beem.2026.102154_bib26","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1259\/0007-1285-24-288-637","article-title":"Orbital X-ray therapy of progressive exophthalmos","volume":"24","author":"Jones","year":"1951","journal-title":"Br J Radiol"},{"issue":"8","key":"10.1016\/j.beem.2026.102154_bib27","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.ophtha.2003.12.054","article-title":"Orbital irradiation for Graves' ophthalmopathy: Is it safe? A long-term follow-up study","volume":"111","author":"Wakelkamp","year":"2004","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.beem.2026.102154_bib28","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1210\/jc.2003-030260","article-title":"Long-term safety of orbital radiotherapy for Graves' ophthalmopathy","volume":"88","author":"Marcocci","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2026.102154_bib29","unstructured":"[Online]. Available: https:\/\/www.rcr.ac.uk\/media\/1trgbgsb\/rcr-publications_recommendations-for-using-radiotherapy-for-benign-disease-in-the-uk_march-2023.pdf."},{"key":"10.1016\/j.beem.2026.102154_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.615993","article-title":"Epidemiolog, Natural History, Risk Factors, and Prevention of Graves\u2019 Orbitopathy","volume":"11","author":"Bartalena","year":"2020","journal-title":"Front Endocrinol"},{"issue":"12","key":"10.1016\/j.beem.2026.102154_bib31","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1210\/jc.2012-2389","article-title":"Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves\u2019 orbitopathy","volume":"97","author":"Bartalena","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2026.102154_bib32","doi-asserted-by":"crossref","DOI":"10.1177\/20420188251383022","article-title":"The role of mycophenolate mofetil in the therapy of thyroid eye disease","volume":"16","author":"Witowska","year":"2025","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.beem.2026.102154_bib33","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S2213-8587(18)30020-2","article-title":"Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves\u2019 orbitopathy (MINGO): a randomised, observer-masked, multicentre trial","volume":"6","author":"Kahaly","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.beem.2026.102154_bib34","first-page":"8","article-title":"Azathioprine in the treatment of thyroid-associated ophthalmopathy","volume":"122","author":"Perros","year":"1990","journal-title":"Acta Endocrinol"},{"issue":"4","key":"10.1016\/j.beem.2026.102154_bib35","first-page":"299","article-title":"Combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED): a multicentre, 2\u00d72 factorial, double-blind, randomised controlled trial","volume":"6","author":"Rajendram","year":"2018","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.beem.2026.102154_bib36","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1365-2362.1986.tb01016.x","article-title":"Ciclosporin and prednisone v. prednisone in treatment of Graves\u2019 ophthalmopathy: a controlled, randomized and prospective study","volume":"16","author":"Kahaly","year":"1986","journal-title":"Eur J Clin Invest"},{"issue":"2","key":"10.1016\/j.beem.2026.102154_bib37","first-page":"422","article-title":"Methotrexate as a corticosteroid-sparing agent for thyroid eye disease","volume":"6","author":"Rivera-Grana","year":"2015","journal-title":"J Clin Exp Ophthalmol"},{"key":"10.1016\/j.beem.2026.102154_bib38","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12902-024-01545-0","article-title":"Combined glucocorticoids and cyclophosphamide in the treatment of Graves\u2019 ophthalmopathy: a systematic review and meta-analysis","volume":"24","author":"Xiang","year":"2024","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.beem.2026.102154_bib39","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13044-025-00273-4","article-title":"Sirolimus for the treatment of Graves\u2019 orbitopathy","volume":"18","author":"Comi","year":"2025","journal-title":"Thyroid Res"},{"issue":"11","key":"10.1016\/j.beem.2026.102154_bib40","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1007\/s40618-022-01862-y","article-title":"Sirolimus as a second-line treatment for Graves\u2019 orbitopathy","volume":"45","author":"Lanzolla","year":"2022","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.beem.2026.102154_bib41","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1046\/j.1365-2249.1996.d01-854.x","article-title":"Randomized trial of intravenous immunoglobulins versus prednisolone in Graves\u2019 ophthalmopathy","volume":"106","author":"Kahaly","year":"1996","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"10.1016\/j.beem.2026.102154_bib42","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1210\/er.2018-00066","article-title":"Insulin-like growth Factor-I receptor and thyroid-associated ophthalmopathy","volume":"40","author":"Smith","year":"2019","journal-title":"Endocr Rev"},{"issue":"1","key":"10.1016\/j.beem.2026.102154_bib43","doi-asserted-by":"crossref","first-page":"105","DOI":"10.7861\/clinmedicine.6-1-105","article-title":"Biologic therapies in autoimmune diseases","volume":"6","author":"Penn","year":"2006","journal-title":"Clin Med"},{"issue":"18","key":"10.1016\/j.beem.2026.102154_bib44","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for thyroid-associated ophthalmopathy","volume":"376","author":"Smith","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.beem.2026.102154_bib45","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.ophtha.2021.10.017","article-title":"Teprotumumab efficacy, safety, and durability in longer-duration thyroid eye disease and re-treatment: OPTIC-X study","volume":"129","author":"Douglas","year":"2022","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.beem.2026.102154_bib46","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1210\/clinem\/dgad637","article-title":"Efficacy and safety of teprotumumab in patients with thyroid eye disease of long duration and low disease activity","volume":"109","author":"Douglas","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.beem.2026.102154_bib47","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2025.2585616","article-title":"Preclinical pharmacology, pharmacokinetics, and pharmacodynamics of veligrotug, a full antagonist antibody to the IGF-1 receptor in development for thyroid eye disease","volume":"17","author":"Kaplan","year":"2025","journal-title":"MAbs"},{"key":"10.1016\/j.beem.2026.102154_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1488220","article-title":"Linsitinib inhibits proliferation and induces apoptosis of both IGF-1R and TSH-R expressing cells","volume":"15","author":"Luffy","year":"2024","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.beem.2026.102154_bib49","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1210\/jc.2014-3014","article-title":"Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves\u2019 orbitopathy: a randomised controlled study","volume":"100","author":"Salvi","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.beem.2026.102154_bib50","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1210\/jc.2014-2572","article-title":"Randomised controlled trial of Rituximab in patients with Graves\u2019 Orbitopathy","volume":"100","author":"Stan","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.beem.2026.102154_bib51","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s42000-021-00282-6","article-title":"Intravenous rituximab therapy for active Graves\u2019 ophthalmopathy: a meta-analysis","volume":"20","author":"Chen","year":"2021","journal-title":"Hormones"},{"key":"10.1016\/j.beem.2026.102154_bib52","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3109\/07435800.2011.635622","article-title":"CD8+CD28-lymphocytes in peripheral blood and serum concentrations of soluble interleukin 6 receptor are increased in patients with Graves\u2019 orbitopathy and correlate with disease activity","volume":"37","author":"Slowik","year":"2012","journal-title":"Endocr Res"},{"key":"10.1016\/j.beem.2026.102154_bib53","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ajo.2018.07.038","article-title":"Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant graves orbitopathy: a randomized clinical trial","volume":"195","author":"Perez-Moreiras","year":"2018","journal-title":"Am J Ophthalmol"},{"issue":"12","key":"10.1016\/j.beem.2026.102154_bib54","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1007\/s40123-025-01255-3","article-title":"Targeting IL-6 receptor signaling with satralizumab in thyroid eye disease: design of the phase 3 SatraGO-1 and SatraGO-2 trials","volume":"14","author":"Ezra","year":"2025","journal-title":"Ophthalmol Ther"},{"issue":"1","key":"10.1016\/j.beem.2026.102154_bib55","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/IOP.0000000000003007","article-title":"Subjective assessment of eight CT features in the prediction of dysthyroid optic neuropathy","volume":"42","author":"Landray","year":"2026","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"2","key":"10.1016\/j.beem.2026.102154_bib56","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3341\/kjo.2012.26.2.73","article-title":"Clinical profile and visual outcomes after treatment in patients with dysthyroid optic neuropathy","volume":"26","author":"Jeon","year":"2012","journal-title":"Korean J Ophthalmol"},{"key":"10.1016\/j.beem.2026.102154_bib57","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.936819","article-title":"Risk prediction of dysthyroid optic neuropathy based on CT imaging features combined the bony orbit with the soft tissue structures","volume":"9","author":"Cheng","year":"2022","journal-title":"Front Med"},{"issue":"3","key":"10.1016\/j.beem.2026.102154_bib58","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/eye.2012.284","article-title":"Acute thyroid eye disease (TED): principles of medical and surgical management","volume":"27","author":"Verity","year":"2013","journal-title":"Eye"},{"issue":"6","key":"10.1016\/j.beem.2026.102154_bib59","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.ajo.2014.02.044","article-title":"Reduced risk of compressive optic neuropathy using orbital radiotherapy in patients with active thyroid eye disease","volume":"157","author":"Shams","year":"2014","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.beem.2026.102154_bib60","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0161-6420(86)33712-6","article-title":"The four stages of surgical rehabilitation of the patient with dys-thyroid ophthalmopathy","volume":"93","author":"Shorr","year":"1986","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.beem.2026.102154_bib61","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jaapos.2006.01.183","article-title":"Strabismus after orbital decompression","volume":"10","author":"Maxwell","year":"2006","journal-title":"J A Assoc Pediatr Ophthalmol Strabis"},{"issue":"01","key":"10.1016\/j.beem.2026.102154_bib62","doi-asserted-by":"crossref","first-page":"040","DOI":"10.1055\/s-0037-1598192","article-title":"Orbital decompression for thyroid eye disease","volume":"31","author":"Braun","year":"2017","journal-title":"Semin Plast Surg"},{"issue":"8","key":"10.1016\/j.beem.2026.102154_bib63","first-page":"1363","article-title":"Orbital decompression surgery for the treatment of Graves\u2019 ophthalmopathy: comparison of different techniques and long-term results","volume":"11","author":"Cubuk","year":"2018","journal-title":"Int J Ophthalmol"},{"key":"10.1016\/j.beem.2026.102154_bib64","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ajo.2023.07.020","article-title":"Preoperative risk factors for proptosis recurrence after rehabilitative orbital decompression in Graves' orbitopathy patients","volume":"258","author":"Byeon","year":"2024","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.beem.2026.102154_bib65","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3109\/01676830.2014.949784","article-title":"Characterization and outcomes of repeat orbital decompression for thyroid-associated orbitopathy","volume":"34","author":"Zhang-Nunes","year":"2015","journal-title":"Orbit"},{"issue":"4","key":"10.1016\/j.beem.2026.102154_bib66","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0002-9394(14)72666-2","article-title":"The incidence of Graves' ophthalmopathy in Olmsted County, Minnesota","volume":"120","author":"Bartley","year":"1995","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.beem.2026.102154_bib67","unstructured":"Wong A.S., Phelps P., Patel U., American Academy of Ophthalmology - eyewiki, [Online]. Available: https:\/\/eyewiki.org\/Upper_Eyelid_Retraction."}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X2600076X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X2600076X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:20:50Z","timestamp":1790608850000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X2600076X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":67,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1521690X2600076X"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2026.102154","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thyroid eye disease: Established and emerging therapies","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2026.102154","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2026 Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102154"}}